PRN: Global Respiratory Disease Partnering Deals and Agreements Entered into by the World's Leading Pharma and Biotechnology Companies 2010-2017 - Research and Markets

06/mar/2017 11:15:12 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Respiratory Disease Partnering Deals and Agreements Entered into by the World's Leading Pharma and Biotechnology Companies 2010-2017 - Research and Markets

 
[06-March-2017]
 

DUBLIN, Mar 06, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Respiratory Partnering 2010-2017: Deal trends, players and financials" report to their offering.

Global Respiratory Partnering 2010 to 2017 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope:

  • Trends in Respiratory dealmaking in the biopharma industry since 2010
  • Analysis of Respiratory deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Respiratory deal contract documents
  • Comprehensive access to over 3500 Respiratory deal records
  • The leading Respiratory deals by value since 2010
  • Most active Respiratory dealmakers since 2010

Key Topics Covered:

Executive Summary

1. Introduction

2. Trends in Respiratory dealmaking

3. Financial deal terms for Respiratory partnering

4. Leading Respiratory deals and dealmakers

5. Respiratory contract document directory

6. Respiratory dealmaking by therapeutic target

For more information about this report visit http://www.researchandmarkets.com/research/f2wkhf/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl